Altimmune, Inc.
ALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $5 | $5 |
| % Growth | 0% | 0% | 0% | – |
| Cost of Goods Sold | $14,960 | $0 | $0 | $0 |
| Gross Profit | -$14,955 | $5 | $5 | $5 |
| % Margin | -299,100% | 100% | 100% | 100% |
| R&D Expenses | $14,960 | $17,236 | $15,827 | $19,781 |
| G&A Expenses | $5,904 | $5,691 | $5,993 | $5,090 |
| SG&A Expenses | $5,904 | $5,691 | $5,993 | $5,090 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$14,960 | $0 | $0 | $0 |
| Operating Expenses | $5,904 | $22,927 | $21,820 | $24,871 |
| Operating Income | -$20,859 | -$22,922 | -$21,815 | -$24,866 |
| % Margin | -417,180% | -458,440% | -436,300% | -497,320% |
| Other Income/Exp. Net | $1,845 | $776 | $1,559 | $1,686 |
| Pre-Tax Income | -$19,014 | -$22,146 | -$20,256 | -$23,180 |
| Tax Expense | $0 | $0 | -$681 | $0 |
| Net Income | -$19,014 | -$22,146 | -$19,575 | -$23,180 |
| % Margin | -380,280% | -442,920% | -391,500% | -463,600% |
| EPS | -0.21 | -0.27 | -0.26 | -0.33 |
| % Growth | 22.2% | -3.8% | 21.2% | – |
| EPS Diluted | -0.21 | -0.27 | -0.26 | -0.33 |
| Weighted Avg Shares Out | 89,418 | 81,478 | 75,548 | 71,261 |
| Weighted Avg Shares Out Dil | 89,418 | 81,478 | 75,548 | 71,261 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,426 | $1,132 | $1,545 | $1,569 |
| Interest Expense | $495 | $264 | $1 | $1 |
| Depreciation & Amortization | $27 | $30 | $29 | $33 |
| EBITDA | -$18,492 | -$21,852 | -$20,226 | -$23,146 |
| % Margin | -369,840% | -437,040% | -404,520% | -462,920% |